X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the Licensing Agreement, Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
Lead Product(s): TPM-1116
Therapeutic Area: Sleep Product Name: TPM-1116
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harmony Biosciences
Deal Size: $393.0 million Upfront Cash: $25.5 million
Deal Type: Licensing Agreement April 11, 2024
Details:
Wakix (pitolisant) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Product Name: Wakix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
Ozawade (pitolisant hydrochloride) enhances the activity of histaminergic neurons, promotes wakefulness by blocking H3 autoreceptors and increases the levels of histamine transmitters at the synapse, and is used for Prader-Willi Syndrome.
Lead Product(s): Pitolisant Hydrochloride
Therapeutic Area: Sleep Product Name: Ozawade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
